Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline

BALTIMORE, Jan. 20, 2022 -- Graybug Vision, Inc. , a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic... | January 20, 2022

Related Keywords

Johns Hopkins University ,Maryland ,United States ,Arizona ,Fang Li ,Anhui ,China ,Redwood City ,California ,Xiamen ,Fujian ,Wuhan ,Hubei ,Nanjing ,Jiangsu ,Baltimore ,Ali Kakavand ,Fred Guerard ,Head Of Program Management ,Program Management ,Arizona State University ,Regulatory Affairs ,Neurosciences Institute ,Johns Hopkins University School Of Medicine ,Nasdaq ,Exchange Commission ,Graybug Research Development ,Wuhan University ,Graybug Vision Inc ,China Pharmaceutical University ,Astrazeneca ,Xiamen University ,Regulatory Affairs At Hurley Consulting Associated Ltd ,Vice President ,Hurley Consulting Associated ,Portfolio Management ,Biomedical Engineering ,Nasdaq Listing Rule ,Johns Hopkins University School ,Private Securities Litigation Reform Act ,Graybug Vision ,Nc Stock Exchange ,News ,Information ,Press Release ,022 ,Raybug ,Iopharmaceutical ,Company ,Ocused ,N ,Developing ,Ransformative ,Medicines ,Or ,The ,Treatment ,F ,Diseases ,Retina ,Nd Gray Us38942q1031 ,